Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 13.87% is 39% above its 5-year average of 9.95%, around the middle of its 5-year range (4.41%–18.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.22% above its 12-month average of 12.81%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.87%.
DEBT TO ASSETS RATIO
13.87%
DEBT TO ASSETS RATIO AVG TTM
12.81%
DEBT TO ASSETS RATIO AVG 3Y
11.05%
DEBT TO ASSETS RATIO AVG 5Y
9.95%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+8.22%
CURRENT VS 3Y AVG
+25.53%
CURRENT VS 5Y AVG
+39.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 808 covered companies
CURRENT VS SECTOR MEDIAN
+15308.00%
vs the sector median at left
DocGo Inc.
Market Cap
$35.78M
Debt to Assets Ratio
13.87%
TTM Avg
12.81%
3Y Avg
11.05%
5Y Avg
9.95%
Market Cap
$36.28M
Debt to Assets Ratio
0.14%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.97M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$37.12M
Debt to Assets Ratio
0.45%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$37.33M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$37.75M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$33.74M
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DocGo Inc. (DCGO) | $35.78M | 13.87% | 12.81% | 11.05% | 9.95% |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | 0.14% | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | 0.00% | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.76M | 0.25% | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | 0.00% | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.12M | 0.45% | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.33M | 0.00% | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $37.75M | 0.00% | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $33.74M | 0.41% | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.66M | 0.05% | N/A | N/A | N/A |
Debt/Assets
13.9%
Debt/Equity
0.22
Current Ratio
1.66
Interest Coverage
-87.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 13.87% |
| 2026-03-31 | 13.62% |
| 2025-12-31 | 13.44% |
| 2025-09-30 | 8.33% |
| 2025-06-30 | 14.81% |
| 2025-03-31 | 14.13% |
| 2024-12-31 | 12.55% |
| 2024-09-30 | 11.54% |
| 2024-06-30 | 10.90% |
| 2024-03-31 | 10.64% |
| 2023-12-31 | 9.48% |
| 2023-09-30 | 5.04% |
| 2023-06-30 | 5.27% |
| 2023-03-31 | 5.01% |
| 2022-12-31 | 5.06% |
| 2022-09-30 | 5.78% |
| 2022-06-30 | 4.41% |
| 2022-03-31 | 5.12% |
| 2021-12-31 | 5.33% |
| 2021-09-30 | 16.24% |
| 2021-06-30 | 18.35% |
| 2021-03-31 | 13.49% |
| 2020-12-31 | 13.87% |
| 2020-09-30 | 62.13% |
